Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab + cemiplimab versus cemiplimab in first-line PD-L1-high advanced NSCLC
2022-501483-18-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Fianlimab + cemiplimab with Cemiplimab + placebo for fianlimab (2 arms). Primary endpoint: Objective response rate. Planned start Mar 2025; status: authorised.
02
Drugs
fianlimabcemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-501483-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501483-18-00.